TriangleAndrogen Deprivation Therapy (ADT) (NCT07237269)
Androgen Deprivation Therapy (ADT) trial for Prostate Cancer (NCT07237269). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for men aged 30 or older with prostate cancer and pelvic lymph nodes that show PSMA uptake but measure under one centimeter. Prior definitive treatment and spread outside pelvic lymph nodes are excluded.
The idea: test stronger hormone suppression alongside radiation. Random assignment gives standard androgen-deprivation therapy alone or adds abiraterone and prednisone; both groups receive radiation. Abiraterone blocks an enzyme needed for testosterone production. Researchers compare five-year failure-free survival, toxicity.
This phase 2 study plans 140 patients. Michael Baine leads in Omaha, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.